Follow

Submissions from 2020

PDF

Biological activity of weekly ONC201 in adult recurrent glioblastoma patients, Yazmin Odia and Minesh Mehta
Full Text Restricted – Available from BHSF IP or login only

PDF

Recent Health Care Expenditure Trends Among Adult Cancer Survivors in United States, 2009-2016, Muni Rubens, Anshul Saxena, Sankalp Das, Chintan Bhatt, Emir Veledar, Peter McGranaghan, Ana Viamonte Ros, Yuliya Linhares, Yazmin Odia, Michael Chuong, Rupesh Kotecha, and Minesh Mehta
Full Text Restricted – Available from BHSF IP or login only

Submissions from 2019

PDF

EBV-positive primary CNS lymphoma restricted to the conus medullaris in an immunocompetent host, Matthew Hall, Lyle Feinstein, Sergio Gonzalez-Arias, and Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only

First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report, Matthew Hall, Yazmin Odia, Doured Daghistani, and Minesh Mehta

PDF

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201, Matthew Hall, Yazmin Odia, and Minesh Mehta
Full Text Restricted – Available from BHSF IP or login only

PDF

Core curriculum guidelines for a required clinical neurology experience, Yazmin Odia
Open Access

PDF

Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations, Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only

Submissions from 2017

PDF

Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options, Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only

PDF

BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors, Ashley Roque and Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only

Submissions from 2016

PDF

Gangliocytomas and Gangliogliomas: Review of Clinical, Pathologic and Genetic Features, Yazmin Odia
Open Access

PDF

Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy, Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only